A multicenter study comparing treatment of patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours with 177Lu-octreotate [Octreotate-Lu-177-DOTA-Tyr-3] versus combined 177Lu-octreotate and capecitabine treatment

Trial Profile

A multicenter study comparing treatment of patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours with 177Lu-octreotate [Octreotate-Lu-177-DOTA-Tyr-3] versus combined 177Lu-octreotate and capecitabine treatment

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2011

At a glance

  • Drugs Capecitabine (Primary) ; Octreotate-Lu-177-DOTA-Tyr-3 (Primary)
  • Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2010 Status changed from planning to completed as reported by ISRCTN: Current Controlled Trials.
    • 01 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top